Abstracts tagged "SLE"

Abstract Number: 772 • 2016 ACR/ARHP Annual Meeting
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Givenchy Maree Garcia, Annalyn Urbano and Evelyn Salido, Section of Rheumatology, University of the Philippines - Philippine General Hospital, Manila, Philippines
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…
Abstract Number: 1214 • 2016 ACR/ARHP Annual Meeting
Autoantibody Reactivities Correlated with SLE Disease Activity Identified By the SLE-key® iCHIP® Platform
Chaim Putterman¹, Pennina Safer², Keren Jakobi², Rachel Sorek², Ilana Gilkaite², Kyle Ferber³, Steve Wallace³, Amanda Harris Altice³, D. Scott Batty³ and Irun R Cohen^2,4, ¹Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray LTD, Rehovot, Israel, ³ImmunArray Inc., Richmond, VA, ⁴Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: We have developed an antigen microarray technology to study antibody profiles to elucidate and diagnose clinical states of SLE patients – the iCHIP® SLE-key®…
Abstract Number: 1798 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review
Sara Hussein¹, Manon Suitner¹, Alexandra Baril-Dionne¹, Mihaela Luminita Popescu¹, Nancy Santesso², Stephanie O. Keeling³, Janet E. Pope⁴, Aurore Fifi-Mah⁵ and Josiane Bourré-Tessier¹, ¹Université de Montréal, Montreal, QC, Canada, ²McMaster University, Hamilton, ON, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Non-traumatic osteonecrosis (ON) is a well-recognized complication in systemic lupus erythematosus (SLE). The reported symptomatic ON prevalence is 10-15% and as high as 44%…
Abstract Number: 2785 • 2016 ACR/ARHP Annual Meeting
Translatable in Vitro Immunocyte Functional Measures of CC-292 and CC-90008 Inhibitors of the Bruton’s Tyrosine Kinase (Btk)/Tec Family and the Pathology Observed in the MLR/Lpr Mouse Model of Systemic Lupus Erythematosus (SLE)
Garth Ringheim¹, Jolanta Kosek², Lori Capone³, Mary Adams^4,5, Eun Mi Hur⁴ and Peter H. Schafer⁵, ¹86 Morris Avenue, Celgene Corporation, Summit, NJ, ²Translational Development, Celgene Corporation, Summit, NJ, ³Celgene Corporation, Summit, NJ, ⁴Inflammation and Immunology Translational Development, Celgene Corporation, Summit, NJ, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: CC-292 and CC-90008 are covalent Btk/Tec family kinase inhibitors that block Btk activity by binding with high affinity to the adenosine triphosphate (ATP) binding…
Abstract Number: 2874 • 2016 ACR/ARHP Annual Meeting
CD16+monocytes Are Enriched and Functionally Exacerbated in Driving B Cell Activation Under Systemic Lupus Erythematosus Condition
Huaqun Zhu¹, Yin Su², Fanlei Hu³ and Liling Xu³, ¹Department of Rheumatology and Immunology/Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ³Peking University People's Hospital, Beijing, China
Background/Purpose: Systemic lupus erythematosus(SLE) was an autoimmune disease characterized by extensive B cell activation and autoantibody production. Human peripheral monocytes could be categorized into three subsets…
Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting
Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Niti Goel^1,2, Brandon Barrett³, Ann Duncan⁴, Margaret-Beth Gallagher¹ and Marsha Mackey³, ¹Quintiles, Inc., Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Quintiles, Inc., Rockville, MD, ⁴Quintiles, Inc., Reading, Berkshire, United Kingdom
Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations. These differences may…
Abstract Number: 1241 • 2016 ACR/ARHP Annual Meeting
Understanding Lupus Patients’ Ability to Work with Numbers
Alexa Meara¹, Mary-Kate Tompkins², Kimberly Fisher², Holly Steigelman², Wael N. Jarjour³, Stacy P. Ardoin⁴ and Ellen Peters⁵, ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²The Ohio State University, Columbus, OH, ³Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematous (SLE) is a heterogeneous disease with high morbidity and mortality affecting approximately 20-150 cases per 100,000 people. The risk of early…
Abstract Number: 1802 • 2016 ACR/ARHP Annual Meeting
Prevalence of CMV in the Ohio State University Lupus Population
Brian LaMoreaux¹, Alexa Meara², Holly Steigelman³, Juliette Yedimenko⁴, Wael N. Jarjour⁵ and Stacy P. Ardoin⁶, ¹Rheumatology, Fellow, Columbus, OH, ²Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴S2056, The Ohio State University, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH, ⁶Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Systemic Lupus Erythematous (SLE) is a clinically variable autoimmune disease occurring predominantly in women of childbearing age. SLE treatment can range from close clinical…
Abstract Number: 2792 • 2016 ACR/ARHP Annual Meeting
Hyperhomocysteinemia in SLE
Michelle Petri¹ and Wei Fu², ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hyperhomocysteinemia has been correlated with the occurrence of blood clots, heart attacks and strokes. We investigated the association of the Hyperhomocysteinemia with other clinical…
Abstract Number: 2878 • 2016 ACR/ARHP Annual Meeting
Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE
Mikhail Olferiev¹, Kyriakos A. Kirou², David Fernandez³, Khalili Leila¹, Dina Greenman¹ and Mary K. Crow⁴, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁴Department of Medicine, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: All lymphocyte populations contribute to SLE pathogenesis, but little is known of the specific gene transcripts particularly involved in each cell type. Activation of…
Abstract Number: 914 • 2016 ACR/ARHP Annual Meeting
Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Seunghee Hong¹, Romain Banchereau¹, Marta M. Guerra², Jane E. Salmon^3,4 and Virginia Pascual¹, ¹Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ²Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: SLE is a systemic autoimmune disease that predominantly affects women in reproductive years. SLE pregnancies result in higher rates of adverse outcomes compared with…
Abstract Number: 1264 • 2016 ACR/ARHP Annual Meeting
Pilot Evaluation Points to Male Specific Educational Programming for Males with SLE
Dariana M. Pichardo¹, Jillian A. Rose², Priscilla Toral¹ and Roberta Horton¹, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Methods: Results: Conclusion: Despite our small sample size, our pilot shows an unmet need for this population, which potentially impacts on…
Abstract Number: 1807 • 2016 ACR/ARHP Annual Meeting
Prevalence of Progressive Multifocal Leukoencephalopathy in Adults and Children with Systemic Lupus Erythematosus
Pooja Mahadeshwar¹, Teja Kapoor¹, Kayla Quinnies², Nicholas Tatonetti², Joyce Hui-Yuen³, Samantha Nguyen¹, Joan Bathon¹, Kayla Neville¹, James Miceli¹, Stacy Tanner⁴ and Anca Askanase¹, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Biomedical Informatics, Columbia University Medical Center, NY, NY, ³North Shore-Long Island Jewish Health System, Lake Success, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY
Background/Purpose: In the era of powerful immunosuppression, opportunistic infections are an increasing concern in Systemic Lupus Erythematosus (SLE). A potentially fatal opportunistic demyelinating disease of…
Abstract Number: 2804 • 2016 ACR/ARHP Annual Meeting
Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years
Eleana Ntatsaki¹, Alba Velo Garcia², Borja del Carmelo Gracia Tello Sr.³, Alan D. Salama⁴ and David A. Isenberg⁵, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, ⁴Centre for Nephrology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), leading to end stage renal failure…
Abstract Number: 2880 • 2016 ACR/ARHP Annual Meeting
Distinct Metabolic Pathways Regulate Lipid Antigen Presentation By Monocytes and B Cells: Implications for SLE Patients with Pre-Clinical Atherosclerotic Plaque
Kirsty Waddington¹, Edward Smith², Sara Croca³, David A. Isenberg⁴, Anisur Rahman⁵, Ines Pineda Torra⁶ and Elizabeth Jury⁷, ¹Clinical Pharmacology and Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Rheumatology, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ⁵Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ⁶Clinical Pharmacology, University College London, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) patients have an increased risk of developing clinically apparent cardiovascular disease (CVD) and subclinical atherosclerotic plaque, detectable by vascular ultrasound…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.